Maria L. Fox

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Impact of Atrial Fibrillation on the Risk of Thrombosis and Bleeding for Patients With Polycythemia Vera and Essential Thrombocytosis in the Real World.

Impact of Atrial Fibrillation on the Risk of Thrombosis and Bleeding for Patients With Polycythemia Vera and Essential Thrombocytosis in the Real World.

Journal: American journal of hematology

Published: January 19, 2026

Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence.

Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence.

Journal: Frontiers in immunology

Published: September 12, 2025

Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia.

Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia.

Journal: HemaSphere

Published: September 04, 2025

Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE).

Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE).

Journal: Hematological oncology

Published: August 27, 2025

JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.

JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.

Journal: Haematologica

Published: July 09, 2025

Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study.

Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study.

Journal: American journal of hematology

Published: June 23, 2025

Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC Study.

Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC Study.

Journal: Transplantation and cellular therapy

Published: May 19, 2025

Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC Study.

Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC Study.

Journal: Transplantation and cellular therapy

Published: May 19, 2025

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Journal: Blood cancer journal

Published: December 15, 2024

Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.

Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 12, 2024

Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies.

Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies.

Journal: Bone marrow transplantation

Published: February 22, 2024

DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study.

DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study.

Journal: Thrombosis and haemostasis

Published: January 08, 2024

Showing 1-12 of 44

Last Updated: 09/26/2026